57 results
8-K
EX-99.1
IMVT
Immunovant Inc
8 Oct 19
Regulation FD Disclosure
4:26pm
Exhibit 99.1
Health Sciences Acquisitions Corporation and Immunovant to Host Joint Conference Call for the
Investment Community on Friday, October … session for the investment community.
To access the webcast, please visit Immunovant's website at www.immunovant.com. Participants may also dial
DEFA14A
EX-99.1
IMVT
Immunovant Inc
8 Oct 19
Additional proxy soliciting materials
4:28pm
Exhibit 99.1
Health Sciences Acquisitions Corporation and Immunovant to Host Joint Conference Call for the
Investment Community on Friday, October … session for the investment community.
To access the webcast, please visit Immunovant's website at www.immunovant.com. Participants may also dial
8-K
EX-99.1
IMVT
Immunovant Inc
2 Feb 21
Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401
6:52am
community. To access the webcast, please visit Immunovant’s website at www.immunovant.com. Participants may also dial in using the numbers provided below
8-K
EX-99.1
IMVT
Immunovant Inc
30 Dec 21
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
7:05am
, January 5th, 2022 at 8 a.m. ET. Following prepared remarks, the call will include a live question-and-answer session for the investment community
8-K
EX-99.2
IMVT
Immunovant Inc
17 Nov 21
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
8:36am
://www.clinicaltrials.gov/ For Investor Audiences Only
5 In-depth Interviews Patient Advisory Council Digital Community Insights Broad approach to understanding
8-K
EX-99.1
qksde4n9jnl4d
30 Mar 20
Regulation FD Disclosure
5:14pm
8-K
EX-99.1
zxk2k 211td
25 Aug 20
Regulation FD Disclosure
9:07am
8-K
EX-99.1
1h3b8u94qv8p7pdqg
9 Aug 21
Company Ended the Quarter With Cash of Approximately $379 Million
6:56am
8-K
EX-99.1
wl3p9kn bh
8 Jun 22
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
635gxrpbj8u4njj4s
1 Jun 21
Results of Operations and Financial Condition
7:36am
8-K
2hz50yn24 09qp
20 Dec 19
Immunovant Sciences Ltd. Closes Transaction with Health Sciences
5:19pm
8-K
EX-10.14
dkcabhyn
20 Dec 19
Immunovant Sciences Ltd. Closes Transaction with Health Sciences
5:19pm
424B3
g8e8tgm4jfjm1gsp3 5k
12 Nov 20
Prospectus supplement
8:32am